



GLP-1

The Revolution

ANNUAL REPORT 2025

believe in life

GLP-1. The Revolution

The introduction of GLP-1 analogues in the early 2000s did more than just refine diabetes care; it sparked a public health revolution. What began as a targeted intervention for Type 2 Diabetes has evolved into a definitive solution for the global obesity crisis—a challenge that affects over 1 billion people today and is projected to impact 4 billion by 2035¹.

The clinical landscape has moved with unprecedented speed. Following the 2014 approval of Liraglutide *Saxenda* for weight management, the launch of Semaglutide *Ozempic* in 2017 and its high-dose counterpart *Wegovy* in 2021 redefined the possibilities of medical weight loss². With the 2023 approval of Tirzepatide *Zepbound*, we have entered an era of clinical efficacy previously only seen in bariatric surgery.

In 2025, over 20 million people globally were utilizing GLP-1 agonists³. This surge is more than a trend; it is a necessary response to an annual global economic burden of \$4.32 trillion driven by obesity-related chronic conditions¹. From cardiovascular disease to hypertension and type 2 diabetes, these therapies are now the frontline defense against the world's leading causes of preventable mortality⁴.

At Galenicum, we recognize that the “GLP-1 Revolution” is now entering its most critical phase: scalability. With the recent emergence of oral formulations, broader insurance coverage, and patent expiration, the focus shifts from selective discovery to massive delivery. Galenicum is uniquely positioned to play a critical role in this shift. Our commitment remains clear: ensuring that these life-changing innovations reach the patients who need them most, across every market.

Sources:

¹ World Obesity Federation. World Obesity Atlas 2024: Global projections and economic impact.

² U.S. Food and Drug Administration (FDA). Post-market drug safety and approval database (2014-2023).

³ J.P. Morgan & Morgan Stanley Research. Biopharma Outlook: The GLP-1 Scaling Era (Q1 2026 Update).

⁴ World Health Organization (WHO). Global Status Report on Noncommunicable Diseases.

A DISTINCTIVE PHARMACEUTICAL COMPANY



Antibiotics The revolution since 1930s

Alexander Fleming's 1928 discovery of penicillin unlocked the world's first "miracle drug." This breakthrough transformed once-fatal infections into treatable conditions, saving billions of lives and shifting the industry from merely treating symptoms to curing disease at its source.

Sources:

"Antimicrobial resistance," World Health Organization (WHO), Fact sheet N°194, April 2014. www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
"Achievements in Public Health, 1900-1999: Control of Infectious Diseases," Morbidity and Mortality Weekly Report (MMWR), CDC, July 30, 1999 / 48(29):621-629. www.cdc.gov/mmwr/preview/mmwrhtml/mm4829a1.htm

THE GRAND JOURNEY

Our adventure began in Barcelona in 2003, when three friends in their twenties decided to start up in the pharmaceutical sector. At a time when the dot-coms were proliferating, Galenicum broke into a fairly traditional space.

Even though in the beginning, the business of Galenicum was limited to trading of active pharmaceutical ingredients (APIs) for generics companies in Spain, the activity very quickly expanded to encompass the full value chain, including: research and development, regulatory affairs, manufacturing and supply of a broad range of medicines in any part of the world.

Our positioning as 'specialty pharma' sums up our ambition in research and development, as well as in operations to fulfil our purpose: to keep improving the quality and affordability of medicines worldwide.

An entrepreneurial free-spirit along with a close, reliable and flexible service to clients, have driven our growth. Today, Galenicum is an ecosystem of several businesses with commercial presence in over 70 countries.

Value chain.

Galenicum provides products and services to clients in the pharmaceutical industry across the value chain.



From our origins to our headquarters:

Three episodes on the history of Galenicum and the transformation of current offices and R&D center.

The Grand Journey.

The first episode of a trilogy of short films about the renovation of an old industrial warehouse to become the new Galenicum headquarters and R&D centre. This one is about how the idea started.



The Grand Renovation.

The second episode where the transformation of the new building is in full swing showing all the buzz and fuzz of a working site.




The Grand Pergamon.

The third and final episode where the new headquarters are revealed and the Galenicumers move in.




MILESTONES



BUSINESS ECOSYSTEM

The Galenicum Ecosystem was established to articulate, organise and take advantage of synergies across our different businesses.

Galenicum ecosystem I. There are 4 different Galenicum businesses operating in the pharma sector.



axium

- **B2B model:** We develop, license and supply to other pharma companies globally providing high quality APIs and FDFs and taking care of the entire value chain.
- Broad portfolio comprising different therapeutic areas and technologies.
- Sales team based in Spain, with global reach.

Info and contacts: www.galenicumaxium.com

SAG

- **B2B model:** We produce and supply high quality FDFs for pharma companies globally.
- Manufacturing facilities nearby Madrid, ready to produce over 150 million packs per year.
- Multipurpose site with different technologies: solids, liquids, nasal sprays, creams and ointments.

Info and contacts: www.galenicumsag.com

Vitae

- **B2C model:** We in-license high quality FDFs and commercialise them under our own brand 'Vitae'.
- Third party distribution deals across Latam, Middle East and Asia.
- Sales teams in Chile, Peru, Colombia, Ecuador, Panama, Guatemala, Honduras and the Dominican Republic, covering pharmacies and hospitals.

Info and contacts: www.galenicumvitae.com

Derma

- **B2C model:** We develop and in-license high quality dermatological products and commercialise them under our own brand 'Galenicum Derma.'
- Third party distribution deals for international expansion.
- Sales team covering the whole territory of Spain and launching in several Latin American countries.

Info and contacts: www.galenicumderma.com

BUSINESS ECOSYSTEM

The Galenicum Ecosystem was established to articulate, organise and take advantage of synergies across our different businesses.

Galenicum ecosystem II. There are 2 different Galenicum businesses operating in the fields of plants and animals.



protekting

- **B2B model:** focused on products and services to help our clients protect and grow crops efficiently.
- We offer high quality and innovative phytosanitary products, as well as turnkey solutions for the entire value chain.
- Present in Spain and Latin America with global reach.

Info and contacts: www.protekting.com

VETILEA

- **B2B2C model:** we partner with vets to sell our products directly and they prescribe the products to the pet owners.
- Nutraceutical products for animal health.
- Sales team covering the whole territory of Spain and launched in 8 international markets.

Info and contacts : www.vetilea.com

A BROAD PORTFOLIO

We offer our clients a broad portfolio of products that cover the majority of therapeutic areas. We represent our range through an image inspired by Leonardo da Vinci's 'Vitruvian Man' that offers the opportunity to visualise the 14 Anatomical Therapeutic Chemical (ATC) classification system groups through the human body.

The colours are related to both the ATC code and to our pharmaceutical product in this group.

Our commitment to provide high quality medicines at an accessible price leads us to pursue continuous improvements in both the characteristics of the product and the manufacturing process.

For example, in the development of complex injectables and peptides in various treatment areas such as diabetes, oncology and the central nervous system (CNS).

We are working to be world leaders in gliptins, glifozines, GLP-1, metformin and paracetamol, which are amongst the most 'essential' medicines globally.

ATC code. The Anatomical Therapeutic Chemical coding is a unique code assigned to a medicine according to the organ or system it works on.

It is maintained by the World Health Organization. Galenicum Vitae business uses the ATC color coding in the packaging of its products for quick differentiation.



ALIMENTARY TRACT
& METABOLISM



BLOOD & BLOOD
FORMING ORGANS



CARDIOVASCULAR
SYSTEM



DERMATOLOGICALS



GENITO URINARY SYSTEM
AND SEX HORMONES
& METABOLISM



ANTI-INFECTIVES
FOR SYSTEM USE



ANTINEOPLASTIC AND
IMMUNOMODULATING
AGENTS



MUSCULO-SKELETAL
SYSTEM



NERVOUS
SYSTEM



RESPIRATORY
SYSTEM



SENSORY
ORGANS



VARIOUS

OUR MOLECULE OFFERING

Over the past years, Galenicum Axiom has significantly intensified its investment in Research & Development. This strategic commitment has been focused on completing a robust portfolio of molecules driven by our expertise across pharmaceutical development, clinical and regulatory fields, with an increasing emphasis on more complex molecules, such as GLP-1s.

As a result of this focused effort, we have successfully expanded our portfolio to include over 60 molecules, with a strong pipeline indicating continued growth and further therapeutic advancements ahead.

Alimentary tract and metabolism

Almagate
Cinitapride
Dapagliflozin
Empagliflozin
Empagliflozin+Metformin
Empagliflozin+Linagliptin
Linagliptin
Linagliptin+Metformin
Liraglutide
Metformin
Semaglutide
Setmelanotide acetate
Sitagliptin
Sitagliptin+Metformin
Tirzepatide
Vildagliptin
Vildagliptin+Metformin
Vonoprazan

Blood and blood forming organs

Cilostazol
Dabigatran
Eltrombopag

Cardiovascular system

Amiodarone
Atorvastatin
Bempedoic Acid
Bempedoic Acid+Ezetimibe
Inclisiran
Manidipine
Ramipril
Rosuvastatin

Dermatologicals

Betamethasone+Calcipotriol

Genito urinary system and sex hormones

Dutasteride
Dutasteride+Tamsulosin
Tamsulosin

Antiinfectives for systemic use

Aztreonam
Caspofungin
Cefixime
Cefiderocol Sulfate Tosylate
Ceftazidime+Avibactam
Ceftolozane+Tazobactam
Dalbavancin
Micafungin
Rezafungin
Tigecycline
Vonoprazan+Amoxicillin

Antineoplastic and immunomodulating agents

Abemaciclib
Anagrelide
Anastrozole
Calcium Levofolinate
Letrozole
Midostaurin
Ruxolitinib
Voclosporin

Musculo-skeletal system

Dexketoprofen
Ibuprofen

Nervous system

Almotriptan
Citicoline
Diazepam
Edaravone
Paracetamol
Remimazolam
Rivastigmine
Tafamidis free acid
Tafamidis meglumine

Respiratory system

Azelastine

Various

Methylene blue


GLOBAL FROM LOCAL

Our company was founded in Barcelona in 2003, where we have our Headquarters and R&D centre. Our manufacturing facility is in San Agustín del Guadalix, near Madrid.

From those two main sites in Spain we manage all our global operations and commercial agreements that reached over 70 countries this past year, mainly through our B2B deals with important pharmaceutical laboratories worldwide.

Additionally, we have a significant presence in Latin America, with local businesses and offices in Santiago (Chile), Lima (Peru), Medellín (Colombia), Quito (Ecuador), and Mexico City (Mexico).

In the past three years we expanded our international footprint with two additional affiliates in Hyderabad (India) and Dubai (UAE).



OUR VALUES

We are who we are and stand where we stand because of our values.

Our values reflect the essence of our culture, which we want to preserve regardless of time and business scale.

Challenge, Connection and Commitment are our core values. Energy, Adaptability and Creativity are the values that boost them. All these 6 values have not been decided by chance, but were identified by a group of over

100 employees as distinctive of Galenicum. Moreover, we added Integrity into the list, the value that encompasses them all, and transcends into the legal space.

Our values contribute to continue gaining ground in our business purpose, but they also guide our day-to-day behaviours, decisions and relationships within and outside our organisation.


Our identity: The core values that define who we are at Galenicum.

CORE VALUES



CHALLENGE

The history of our company is proof of this.



CONNECTION

Partners, customers and suppliers; we are all people beyond our roles in the workplace.



COMMITMENT

Engagement with the company purpose across the organisation. Giving the extra mile.

BOOSTER VALUES



ADAPTABILITY

We understand change as an opportunity. We listen and adapt to keep improving.



ENERGY

Passionate and strongly committed to our company's projects and growth.



CREATIVITY

Remarkable at our R&D department, but truly spread across all areas in the organisation.


ENCOMPASSING VALUE



INTEGRITY

Do 'the right thing', even when nobody is watching

STORIES OF THE YEAR



Statins The revolution since 1980s

Statins revolutionized 20th-century medicine. By blocking the fundamental biological mechanism for cholesterol production, this class of drugs made long-term wellness achievable for millions worldwide, turning fatal risks into manageable conditions. With tens of millions of lives saved, statins demonstrated the power of addressing the roots of disease rather than merely mitigating its effects.

Sources:

"Statins and cardiovascular prevention: impact on mortality," *British Journal of Clinical Pharmacology*, 2021
"2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol," *Circulation*, 2019.
www.ahajournals.org/doi/10.1161/CIR.0000000000000625

STORY 1

DEMOCRATIZING GLP-1 ACCESS

Galenicum is positioned as a key player in the upcoming generic GLP-1 market, a segment expected to bring significant price reductions and broader access to life-changing therapies for diabetes and obesity worldwide.

Though GLP-1s present technical complexity, their generic versions are anticipated to achieve high consumer volumes with characteristic low margins. Galenicum views these products as following the future market dynamics of essentials like Paracetamol or Metformin—a landscape in which the company is highly experienced and prepared to succeed.

Galenicum Axiom - Galenicum B2B business - is strategically preparing for launches of generic liraglutide and semaglutide across Europe, the USA, and Latin America by 2027. Galenicum also plans to file for tirzepatide in 2026 on the NCE-1 date, and for semaglutide tablets in Q2 2027. This plan is backed by heavy investment in its GLP-1 development pipeline, despite the inherent operational complexities of multi-party GLP-1 supply chains.


A key element supporting this plan is a recent licensing and supply agreement with Lupin Limited for injectable Semaglutide, covering 23 countries, including major markets in Canada, Europe, Southeast Asia, and Latin America. In this vital partnership, Galenicum is responsible for overseeing the development, manufacturing, and supply of the Finished Formulations.

Beyond this deal, the company has already secured agreements with over 20 global B2B customers, including deals in the biggest markets like the US, ensuring robust economies of scale.


As co-founder Joaquim Domingo stated, “The partnership with Lupin is a cornerstone of our strategy to scale high-impact volumes of Semaglutide globally. Galenicum’s ambition is clear: to be a leader in the Business-to-Business (B2B) GLP-1 space. The company is dedicated to providing its partners with the necessary reliability, scale, competitiveness, and quality to drive the worldwide transformation of patient care in the diabetes and obesity sectors”.

Galenicum Axiom is committed to improving global patient health by providing reliable and affordable therapeutic options. The company achieves this through a diversified portfolio of over 60 own-developed molecules spanning key therapeutic areas, including cardiovascular, central nervous system, pain management, anti-infectives, and recently placing a particularly strong focus on the field of diabetes, evidenced by significant developments on GLP-1s. The company's operations are supported by state-of-the-art facilities, including dedicated R&D and manufacturing centers powered by a talented team.

Bridging the Gap in the GLP-1 Therapy



Galenicum GLP-1 Roadmap



STORY 2

EFFICIENCY MEETS PLANET

2025 has been a year of profound transformation at our manufacturing plant in San Agustín de Guadalix (SAG), Madrid. Aligned with Galenicum Group ESG strategy, we have embedded sustainability into the core of our business: the more efficient our operations, the lower our environmental footprint.

Resource Efficiency: Doing More with Less

Throughout the year, the SAG site implemented key technical upgrades that yielded significant reductions in utility consumption, proving that operational excellence and planet-care go hand in hand:

- **Water (-13%):** Achieved through new cleaning recipes and a Water Reclamation system, a cross-functional effort between Industrial Development and Production that will continue to evolve through 2027.
- **Electricity (-11%):** Driven by HVAC optimization and smart equipment. Currently, 23-26% of our energy is self-generated via solar panels; on peak sunny days, the plant operates 100% on clean energy.
- **Gas (-3%):** Lowered through heat recovery projects, “recycling” heat from air compression processes to warm our offices and warehouse.


Closing the Loop: From Waste to Value

Beyond utilities, we have evolved our management model to prioritize Circular Economy and our Zero Waste commitment. By refining segregation at the source, we ensure materials are reintroduced into the value chain:

- **Material Recovery:** Paper and cardboard are transformed into recycled pulp, plastics into industrial pellets (granza), and wood is converted into fuel for energy recovery, displacing fossil fuels.
- **Hazardous Waste Reduction:** A major technical milestone was the reclassification of waste streams. By overcoming previous treatment limitations, we successfully declassified materials from hazardous to non-hazardous, significantly reducing our environmental impact.
- **Packaging Lifecycle:** We conducted an exhaustive Circular Economy Study on our drums based on API/ excipient characteristics and ADR classifications. This allows us to optimize internal reuse for other waste fractions, maximizing the life cycle of every container before its final recycling.

These milestones represent the dedication of our teams to improve operations while protecting our environment. At Galenicum SAG, we are not just manufacturing life-changing medicines; we are building a cleaner, more resilient future for the pharmaceutical industry

Production vs. Electricity Consumption Efficiency (SAG)



Production Volume vs. Unit Electricity consumption per 1000 units (SAG Plant, 2022–2025).

STORY 3

NEW FRONTIERS

2025 has been a transformative year for Galenicum Vitae, scaling our impact across new frontiers. From the successful launch in Mexico alongside PiSA to the strategic activation of Hub America, our operational footprint is expanding. With our Chilean operations approaching the €25M milestone and significant breakthroughs in our Oncology portfolio, we are solidifying our position as a high-value global partner.

A cornerstone of this year's success is our strategic momentum within the AMEA region. We are proud to announce a major milestone with our first dossiers submissions in Saudi Arabia. Last October 2025 our partner Cigalah officially submitted the registration file for Sitavitae (Sitagliptin) 50mg & 100mg in the country.

This submission represents our first decisive step into one of the region's most dynamic pharmaceutical markets. While we anticipate a thorough regulatory process—targeting approval by the second half of 2027—this move lays the groundwork for our long-term vision to launch a dedicated subsidiary in Saudi Arabia in 2029.

III Edition of 'Puentes en Salud': A forum for exchanging expertise and advancing the evolution of medicine.



Our commitment to a multi-regional strategy is the foundation for Galenicum Vitae's goal of becoming a truly global pharmaceutical leader. This growth is driven by a strong portfolio of bioequivalent pharmaceutical products marketed under our own 'vitae' brand. By 2025, we reached over 900 Marketing Authorizations, covering over 30 countries across Latin America, the Middle East, Africa, and Asia.

By combining local expertise with our global standards of excellence, we are ensuring that life-changing therapies reach the patients who need them most.



STORY 4

TACROLIMUS 0.1% EMULSION

Galenicum Derma has reached a new milestone in dermatology with the launch of Tacgalen, the first tacrolimus in microemulsion in Spain (1). Specifically indicated in adults for scalp psoriasis, this 2025 launch represents a major breakthrough in the treatment of complex skin pathologies.

While traditional tacrolimus has historically been formulated as an ointment—making application difficult in hairy areas—Tacgalen's innovative liquid texture enhances adherence. This cutaneous emulsion allows for easy application and significantly better patient compliance, offering a non-invasive, steroid-free alternative. By eliminating greasy residue, it directly improves patient quality of life.

The launch of Tacgalen significantly strengthens Galenicum Derma's position as a leader in prescription dermatology in Spain, offering corticosteroid-free solutions and marking a new chapter in hairy areas management. The need for this innovative product is driven by the reality that psoriasis affects over 1 million people in Spain, representing a substantial 2.3% prevalence rate.

Tacgalen establishes Galenicum Derma as a laboratory offering a comprehensive 360° approach to reddened skin with dry flaking through a synergistic portfolio:

- Prescription: Tacgalen, providing advanced pharmacological control during acute flare-ups with a unique galenic form.
- Nutraceuticals: Probiasor, a cutting-edge oral probiotic specifically formulated to extend remission periods from within.
- Dermocosmetics: Psorium, a specialized range designed for daily skin barrier maintenance and long-term health.

Galenicum Derma is dedicated to turning clinical innovation into affordable, life-changing solutions for patients as we grow our presence in the Spanish dermatological market. Furthermore, the company is actively pursuing global expansion, highlighted by a successful launch in Chile and promising opportunities worldwide.



Source:

¹ Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Ficha técnica Tacgalen 1 mg/ml emulsión cutánea. Centro de Información Online de Medicamentos (CIMA). <https://cima.aemps.es>

STORY 5

LOOK INWARD TO MOVE FORWARD

“Introspection” has become a principle and a recurring practice at Galenicum. We believe that true progress starts from within.

We developed the ‘Introspection Day’ concept back in 2024 to intentionally create the space to reconnect with our purpose, and our drive for continuous improvement. ‘Introspection Days’ are now a new format for collaboration and innovation across the company, making our organization fresher, more cohesive, and more resilient.

In 2025, Galenicum consolidated these ‘Introspection’ sessions as a tool to align corporate culture beyond our day to day operations - Goals, Values, Innovation and Sustainability topics in a collaborative format. These annual events serve as a platform to look inward, to move forward:

- March | “Recharge & Refocus”: This session addressed our corporate values and code of ethics. It ensured that our growth is not compromising our foundational identity and long-term objectives. To liven up the session, we included a surprise batucada performance that energized all attendees.
- July | “Decoding AI”: A new step in our digital transformation. In collaboration with Google and Devoteam, we pushed AI adoption linked to our real needs and specific use cases, at that time testing basic AI applications within the Gemini environment. The team challenge generated interesting and fun outputs involving business cases, reports, and video generation.
- November | “This Is Life”: Dedicated to our refreshed ESG strategy, this session focused on resource optimization, sustainable energy, and responsible supply chain management. Pablo Rosado led a session on ‘From Data to Impact: How to Expand Our Social and Environmental Contribution’. Highlighting our social commitment, a blood donation was organized for that day in our headquarters with Banc de Sang i Teixits. According to their tracing, our blood directly benefited 117 patients in Barcelona.

2025 Introspection Journey: Aligning our Values, Decoding AI with Google, and Expanding our Social Impact through ESG.



KEY FIGURES BY BUSINESS UNIT

Antiretrovirals The revolution since 1990s

The development of potent retroviral therapies since the 1990s revolutionized HIV treatment, turning a once-fatal diagnosis into a manageable chronic condition. Central to this paradigm shift was the pioneering use of drug “cocktails”—Highly Active Antiretroviral Therapy (HAART)—that successfully block viral replication. This critical pharmaceutical breakthrough has saved millions of lives globally, redefined antiviral strategies, and is the cornerstone of modern complex virus care.

Source:

Based on global epidemiological data from UNAIDS and pivotal clinical studies published in *The Lancet* and *The New England Journal of Medicine* (circa 1996-1998).



BUSINESSES

6  All Business4  Pharma1  Plants1  Animals

PEOPLE

84%  Based in Spain+900  Employees52%  Women

REVENUES

11%  Last year growth303M  Consolidated revenues 2025

2031
14,8%  % CAGR Next 5 years
654M€  Consolidated Revenues 2031

FOOTPRINT

60%  Exports73  Countries

INVESTMENTS

47M  Capex 2025

REVENUES

224M  Revenues 2025

2031
12,7%  % CAGR Next 5 years
380M€  Revenues 2031

FOOTPRINT

83%  Exports +80  Countries with ongoing deals 73  Countries with ongoing supplies

CUSTOMERS

198  B2B customers +80  B2B agreements in 2025

R&D

+30  Active R&D projects per year 55  Active patents

FDF

+60  Molecules in Portfolio 134  Marketing authorisations granted 2025 38  Dossiers ready

API

131  Commercial products 320  MT distributed 40  Suppliers

REVENUES

132M  Revenues 2025

2031

10,4%  % CAGR Next 5 years

237M€  Revenues 2031

FOOTPRINT

+50  Countries with ongoing supplies

CUSTOMERS

+100  B2B customers

PRODUCED UNITS

+50  Pharmaceutical forms

97,5M
 Tablets  Liquids
 Capsules  Creams
Total 2025

720  SKUs

CAPACITY

+150M  Packs

REVENUES

16%  Last year growth

43M  Revenues 2025

2031

20,1%  % CAGR
Next 5 years

120M€  Revenues 2031

FOOTPRINT

32  Countries

2  New markets
with distribution
deals

64%  Pallets
in sea
containers vs

36%  Pallets
in planes

CUSTOMERS

16  Distribution
deals

7.1M  Units sold

PRODUCTS

27  Launched

32  SKUs
launched

172  Marketing
Authorizations
granted 2025

918  Marketing
Authorizations
Cumulative
by 2025

REVENUES

69%  Last year growth

27M  Revenues 2025

2031
11,1%  % CAGR Next 5 years
60M€  Revenues 2031

FOOTPRINT

5  Countries

CUSTOMERS

+2000  Total Customers

PRODUCTS

69  SKUs in the market

6  Launches in 2025

6  Future launches

THE REVOLUTION



Antibiotics
The revolution since 1930s



Statins
The revolution since 1980s



Antiretrovirals
The revolution since 1990s



GLP-1
The revolution since 2020's

www.galenicum.com
hello@galenicum.com

believe in life

Galenicum